The Global Antibiotics
Market generated $42,335 million in 2017, and is projected to reach
$50,374 million by 2025, growing at a CAGR of 2.1% from 2018 to 2025. The beta
lactam & beta lactamase inhibitors segment accounted for more than
three-fifth of the total market share in 2017.
Antibiotic is a medication used to either inhibit or prevent
bacterial infections referred as bactericidal and bacteriostatic antibiotics,
respectively. Various types of antibiotics such as penicillin, cephalosporin,
carbapenem, and monobactam are available in pharmacies and hospitals that are
used to treat infectious diseases.
Download PDF Report
Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/5072
The antibiotics market is expected to exhibit significant growth
during the forecast period, due to rise in demand for new generation
antibiotics that can resolve the issue of antimicrobial resistance. In
addition, development of novel approaches for new antibiotics for treating
bacterial infections and increase in number of clinical trials supplement the
growth of the antibiotics market. However, development of antibiotic
resistance, driven by misuse of antibiotics, and time taken for the regulatory
approval restrain the market growth. On the contrary, the discovery of advanced
prospect molecules and introduction of novel combination therapies to treat
antibiotic-resistant microbial infections are expected to provide new
opportunities for market players in the near future.
Based on class, the global antibiotics market is categorized
into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and
others. The quinolones segment is anticipated to exhibit the highest CAGR
during forecast period, due to upsurge in demand for broad-spectrum,
bactericidal activity; new generation quinolones; enhanced oral
bioavailability; superior tissue penetration; and improved safety &
tolerability.
By route of administration, the market is classified into oral,
intravenous, and others. The intravenous segment was the major revenue
contributor in 2017, and is projected to continue this trend during the
forecast period, due to increase in incidence of severe infections. Moreover,
as intravenous antibiotics are administered in higher concentrations, they
reach in the tissues faster as compared to oral antibiotics.
Asia-Pacific is expected to remain dominant throughout the
forecast period attributable to increased antibiotics consumption, their easy
availability, and rise in sale of over-the-counter drugs. However, LAMEA is
expected to experience the highest growth rate during the forecast period,
majorly due to no obligations on antibiotics use in this region.
The report provides a comprehensive analysis of the key players
operating in the global antibiotics market, namely, Abbott Laboratories,
Allergan Plc., F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co.
Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and
Teva Pharmaceutical Industries Ltd.
The other players in the value chain include Aurobindo Pharma,
Bayer HealthCare, Eli Lilly, Lupin Pharmaceuticals, Sun Pharmaceutical,
Shionogi, and others.
Key Findings of the Antibiotics Market :
- Based on spectrum of activity, the
broad-spectrum antibiotic segment is expected to experience rapid growth
in the market, and is projected to grow at a CAGR of 2.4% from 2018 to
2025.
- Depending on route of
administration, the oral segment is expected to exhibit the highest CAGR
during the forecast period.
- By drug origin, the semisynthetic
segment was the major revenue contributor in 2017, and is anticipated to
continue this trend during the forecast period.
- U.S. generated the highest revenue
in the global antibiotics market in 2017, accounting for more than
one-fifth of the global market in 2017.
- LAMEA is estimated to grow at a
CAGR of 3.5% during the forecast period.
No comments:
Post a Comment